← 治験一覧に戻る
特定の悪性腫瘍におけるTNO155とスパルタリズマブまたはリボシクリブの併用療法の第Ib相試験
基本情報
- NCT ID
- NCT04000529
- ステータス
- 中止
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 122
- 治験依頼者名
- Novartis
概要
This study was a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors. These two treatment arms enrolled subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity. The study treatment was administered until the subject experienced unacceptable toxicity, progressive disease, and/or had treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent.
対象疾患
Non-small Cell Lung CarcinomaHead and Neck Squamous Cell CarcinomaEsophageal SCCGastrointestinal Stromal TumorsColorectal Cancer
介入
TNO155(DRUG)
Spartalizumab(DRUG)
Ribociclib(DRUG)
依頼者（Sponsor）
ノバルティスファーマ株式会社(INDUSTRY)